TrialHealth and quality of life outcomes2026

Health-related quality of life in immunocompromised adults with mild-moderate COVID-19 treated with nirmatrelvir-ritonavir: results from the randomized, double-blinded EPIC-IC trial.

Ruth Mokgokong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.